Abstract
The COVID-19 pandemic is associated with neurological symptoms and complications including stroke. There is hypercoagulability associated with COVID-19 that is likely a “sepsis-induced coagulopathy” and may predispose to stroke. The SARS-CoV-2 virus binds to angiotensin-converting enzyme 2 (ACE2) present on brain endothelial and smooth muscle cells. ACE2 is a key part of the renin angiotensin system (RAS) and a counterbalance to angiotensin-converting enzyme 1 (ACE1) and angiotensin II. Angiotensin II is proinflammatory, is vasoconstrictive, and promotes organ damage. Depletion of ACE2 by SARS-CoV-2 may tip the balance in favor of the “harmful” ACE1/angiotensin II axis and promote tissue injury including stroke. There is a rationale to continue to treat with tissue plasminogen activator for COVID-19-related stroke and low molecular weight heparinoids may reduce thrombosis and mortality in sepsis-induced coagulopathy.
Original language | English (US) |
---|---|
Pages (from-to) | 322-325 |
Number of pages | 4 |
Journal | Translational Stroke Research |
Volume | 11 |
Issue number | 3 |
DOIs |
|
State | Published - Jun 1 2020 |
Keywords
- Angiotensin-converting enzyme 2 (ACE2)
- COVID-19
- Coagulopathy
- SARS-CoV-2
- Sepsis
- Stroke
ASJC Scopus subject areas
- Neuroscience(all)
- Clinical Neurology
- Cardiology and Cardiovascular Medicine